Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progression

29 Jan 2024

Abstract excerpt

BACKGROUND/AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by fat accumulation in the liver. MASLD encompasses both steatosis and MASH. Since MASH can lead to cirrhosis and liver cancer, steatosis and MASH must be distinguished during patient treatment. Here, we investigate the genomes, epigenomes, and transcriptomes of MASLD patients to identify signature gene set for more...

Topics

Join the communities discussing this publication.

Cardiovascular Disease and Adiposity
Genetic Associations and Epidemiology
Liver Disease Diagnosis and Treatment

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 38281815
DOI: 10.3350/cmh.2023.0449

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progressionPMID 38281815Read ↗

Comprehensive meta-analysis reveals distinct gene expression signatures of MASLD progressionSemantic proximity Read ↗

Identifying disease progression biomarkers in metabolic associated steatotic liver disease (MASLD) through weighted gene co-expression network analysis and machine learningSemantic proximity Read ↗

Integrative multi-omics and multi-trait analysis prioritizes regulatory mechanisms and genes for metabolic dysfunction-associated steatotic liver diseaseSemantic proximity Read ↗

Molecular Clustering of Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Transcriptome AnalysisSemantic proximity Read ↗

MegaMASLD: An interactive platform for exploring stratified transcriptomic signatures in MASLD progressionSemantic proximity Read ↗

UK Biobank-Based Genetic and Proteomic Network Insights into Metabolic Dysfunction-Associated Steatotic Liver Disease Pathogenesis.Semantic proximity Read ↗

Identification and validation of efferocytosis-related biomarkers for the diagnosis of metabolic dysfunction-associated steatohepatitis based on bioinformatics analysis and machine learningSemantic proximity Read ↗

A prognostic molecular signature of hepatic steatosis is spatially heterogeneous and dynamic in human liverSemantic proximity Read ↗

Profiling the genome and proteome of metabolic dysfunction-associated steatotic liver disease identifies potential therapeutic targetsSemantic proximity Read ↗

Identification of EGR1 as a Key Diagnostic Biomarker in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Through Machine Learning and Immune AnalysisSemantic proximity Read ↗

A liver secretome gene signature-based approach for determining circulating biomarkers of NAFLD severitySemantic proximity Read ↗

Key genes associated with non-alcoholic fatty liver disease and hepatocellular carcinoma with metabolic risk factorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.